Verition Fund Management
MBX

Verition Fund Management’s MBX Biosciences MBX Stock Holding History

Verition Fund Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,600
Closed -$186K – 4032
2025
Q3 		$186K Buy
+10,600
New +$142K ﹤0.01% 3501

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Verition Fund Management's MBX Position: Q1 2026 in Review

Verition Fund Management reduced its MBX Biosciences (MBX) stake by 82% in Q1 2026, selling an estimated $1.61M and leaving 10,222 shares worth $305K. The position accounts for ﹤0.01% of the portfolio, ranked #1771.

Verition Fund Management first reported a position in MBX in Q1 2025 and has held it in 3 quarters since. The position peaked at $1.82M in Q4 2025. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • Verition Fund Management held 10,222 shares of MBX Biosciences worth $305K as of Q1 2026.
  • Verition Fund Management sold 47,353 MBX Biosciences shares in Q1 2026, an estimated $1.61M.
  • MBX Biosciences made up ﹤0.01% of Verition Fund Management's portfolio in Q1 2026, its #1771 holding.
  • Verition Fund Management first reported a position in MBX Biosciences in Q1 2025 and has held it in 3 quarters since.
  • Verition Fund Management's MBX Biosciences position peaked at $1.82M in Q4 2025.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.